Senseonics Holdings Inc (NYSE: SENS) Announces Exhibition of PROMISE Facts at the American Diabetes Association 81st Technical Sittings

Senseonics Holdings Inc (NYSE: SENS) today announced an additional demonstration of PROMISE Study facts assessing the next generation Eversense CGM System at the American Diabetes Association Simulated 81st Annual Technical Meetings.

Data presented by Satish Garg MD

The data assessing the security and correctness of the next generation Eversense system was offered by Satish Garg, MD, Professor of Medicine at the Barbara Davis Center of the University of Colorado, Denver, and the PROMISE study group Principal Investigator (PI).

The company offered formerly released information demonstrating presentation identical to the current 90-day feeler obtainable in the United States, with abridged standardization, down to one per day, with length extended to 180 days.

The Eversense CGM System comprises a fluorescence-based device, an intelligent mast sported over the device to enable data communication, and a mobile app for showing glucose standards, tendencies, and warnings. The scheme is also the first to feature a clever transmitter that offers wearers inconspicuous on-body vibratory warnings for high and low glucose and can be detached, revitalized, and re-attached to the skin without dumping the sensor.

“The worth of CGM for patients with diabetes, particularly those necessitating insulin, is undisputed,” said study PI, Dr. Satish Garg. “To permit more patients to use CGM, there wishes to be choice in creation features. The correctness outline established by Eversense in the PROMISE Study authenticates the role that long-term implantable CGM systems can play in assisting persons manage their glucose stages.”

Report outcomes

Complete mean absolute relative difference (MARD) against orientation worth was 9.1% for the primary sensor over 49,000 balancing points and 8.5% for the SBA sensor over 12,000 balancing points.

The percent sensor interpretations within 20 mg/dL or 20% of orientation values (20/20% agreement rate) were as ensues:

Across the whole 40-400 mg/dL variety, the arrangement rate was 92.9% for the primary sensor and 93.9% for the SBA sensor.

In the hypoglycemic ranges of 40-60 mg/dL and 61-80 mg/dL, the arrangement rates were 89.4% and 92.2% for the primary sensor and 96.5% and 96.8% for the SBA sensor, correspondingly.

The confirmed hypoglycemic alert detection rate was 93% for the primary sensor and 94% for the SBA sensor.

Leave a Comment

Your email address will not be published.